SCHEMBL3377507

SCHEMBL3377507

CCOC(=O)C1=C(COCCN)N(OS(=O)(=O)c2ccccc2)C(C)=C(C(=O)OC)C1c1ccccc1Cl

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 4/20 0.61
NR1I2 O75469 2/20 0.61
TBXA2R P21731 3/20 0.59
ADRA1A P35348 3/20 0.59
SLC6A3 Q01959 3/20 0.59
ADORA3 P0DMS8 3/20 0.59
HTR1A P08908 2/20 0.59
ADRA2A P08913 2/20 0.59
CHRM1 P11229 2/20 0.59
DRD1 P21728 2/20 0.59
SLC6A2 P23975 2/20 0.59
OPRM1 P35372 2/20 0.59
DRD3 P35462 2/20 0.59
KCNH2 Q12809 2/20 0.59
ABCB11 O95342 2/20 0.59
ABCB1 P08183 2/20 0.59
ADRB3 P13945 2/20 0.59
OPRK1 P41145 2/20 0.59
SCN5A Q14524 2/20 0.59
KCNK2 O95069 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5459829 0.85 TBXA2R (0.60) CYP3A4NR1I2TBXA2RADRA1ASLC6A3
SCHEMBL19687545 0.84 TBXA2R (0.66) CYP3A4NR1I2TBXA2RADRA1ASLC6A3
SCHEMBL9761425 0.83 TBXA2R (0.59) CYP3A4NR1I2TBXA2RADRA1ASLC6A3
SCHEMBL7308054 0.77 TBXA2R (0.51) CYP3A4NR1I2TBXA2RADRA1ASLC6A3
SCHEMBL9759993 0.77 CYP2C9 (0.52) CYP3A4NR1I2TBXA2RADRA1ASLC6A3
SCHEMBL30516334 0.77 TBXA2R (0.56) CYP3A4NR1I2TBXA2RADRA1ASLC6A3
SCHEMBL3181833 0.77 NR1I2 (0.51) CYP3A4NR1I2TBXA2RADRA1ASLC6A3
SCHEMBL25377373 0.76 TBXA2R (0.90) CYP3A4NR1I2TBXA2RADRA1ASLC6A3
SCHEMBL28342101 0.76 TBXA2R (0.60) CYP3A4NR1I2TBXA2RADRA1ASLC6A3
Amlodipine SCHEMBL1560959 0.76 CYP3A4 (1.00) CYP3A4NR1I2TBXA2RADRA1ASLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117945986-A Crystal form of maleic acid levamlodipine and preparation method and application thereof 常州瑞明药业有限公司 2024-04-30 CN disclosed
CN-114478571-B Preparation method of amlodipine besylate degradation impurities and detection method of impurities in amlodipine besylate 安徽美致诚药业有限公司 2023-07-28 CN disclosed
CN-116332832-A Maleic acid levo-amlodipine amorphous crystal form and preparation method thereof 安徽美致诚药业有限公司 2023-06-27 CN disclosed
CN-115974769-A Levamlodipine maleate crystal form, and preparation method and application thereof 常州瑞明药业有限公司 2023-04-18 CN disclosed
CN-115850159-A Preparation method of levamlodipine maleate 常州瑞明药业有限公司 2023-03-28 CN disclosed
CN-114478571-A Preparation method of amlodipine besylate degradation impurities and detection method of impurities in amlodipine besylate 安徽美致诚药业有限公司 2022-05-13 CN disclosed
US-9314454-B2 Oral cavity disintegrating tablet and method of producing the same SAWAI PHARMACEUTICAL CO., LTD. (JP) 2016-04-19 US disclosed
EP-2233129-B1 ORAL CAVITY DISINTEGRATING TABLET AND METHOD OF PRODUCING THE SAME SAWAI SEIYAKU KK (JP) 2014-05-07 EP disclosed
US-20100278930-A1 ORAL CAVITY DISINTEGRATING TABLET AND METHOD OF PRODUCING THE SAME SAWAI PHARMACEUTICAL CO., LTD. (JP) 2010-11-04 US disclosed
EP-2233129-A1 ORAL CAVITY DISINTEGRATING TABLET AND METHOD OF PRODUCING THE SAME Sawai Pharmaceutical Co., Ltd. (JP) 2010-09-29 EP disclosed
EP-0993447-B1 A PROCESS FOR THE PREPARATION OF AMLODIPINE BENZENESULPHONATE ADAMED SP ZOO (PL) 2005-08-17 EP disclosed
US-5391548-A Transdermal flux enhancing compositions to treat hypertension, diabetes and angina pectoris PFIZER INC. (US) 1995-02-21 US disclosed
EP-0271983-B1 TRANSDERMAL FLUX ENHANCING COMPOSITIONS PFIZER INC. (US) 1991-06-12 EP disclosed